Exonate
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Wtl Moorfield Rd, Duxford, Cambridgeshir...Phone Number
+44 1223734710Website
www.exonate.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Exonate
Exonate is a biopharmaceutical company dedicated to developing innovative treatments for retinal vascular diseases, particularly focusing on Age Related Macular Degeneration and diabetic eye diseases. Their lead product, EXN407, aims to be the first topical therapy for conditions like diabetic retinopathy and is expected to enter Phase IIb clinical trials in 2026. The company specializes in small molecule drugs that modulate alternative mRNA splicing to combat diseases characterized by pathological blood vessel formation. Exonate's mission is to transform the lives of patients suffering from vision loss by addressing high unmet medical needs.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Exonate your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if Exonate has recently received funding, and reach out quickly before it becomes old news!
Exonate, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Exonate recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Exonate
Funding: Get notified immidiatlly once Exonate has new funding data
Check out if Exonate is spiking on competitors!
Click to see if Exonate had a recent Job posting/layoffs
Product Launch: Get notified when Exonate launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Exonate
Compare insights from companies similar to Exonate, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Exonate
<$5M
11-50
Private
$6.8M
2013
N/A
Company Profile Activity
Activity Insights
Exonate is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Exonate is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Exonate.
Exonate financials insights
Gather financial insights about Exonate, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Angel/Seed
$660K
2017
Grant
$6.1M
Exonate Tech Stack
A closer look at the technologies used by Exonate
Exonate News & Media
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
CAMBRIDGE, England & NOTTINGHAM, England--(BUSINESS WIRE)--Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the data from a successful Phase Ib/IIa trial for lead candidate EXN407. These data demonstrate the safety and tolerability of EXN407, as well as clear indications of biological activity, positioning it well for further development as the first topical treatment for retinal vasculExonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO)
Exonate, an early stage biotechnology company, announced today that it has entered into a strategic collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Through the collaboration, Exonate will work with Janssen Research & Development, LLC scientists to develop an eye drop treatment for retinal vascular diseases such as wet AMD and DMO by using mRNA targeted therapies. Exonate has developed small molecules that inhibExonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO)
CAMBRIDGE, England, Jan. 13, 2020 /PRNewswire/ -- Exonate, an early stage biotechnology company, announced today that it has entered into a strategic collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Through the...Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO)
Exonate, an early stage biotechnology company, announced today that it has entered into a strategic collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Through the collaboration, Exonate will work with Janssen Research & Development, LLC scientists to develop an eye drop treatment for retinal vascular diseases such as wet AMD and DMO by using mRNA targeted therapies. Exonate has developed small molecules that inhib
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Exonate
Sign Up For FreeTo access detailed company insights
Exonate is a biopharmaceutical company dedicated to developing innovative treatments for retinal vascular diseases, particularly focusing on Age Related Macular Degeneration and diabetic eye diseases. Their lead product, EXN407, aims to be the first topical therapy for conditions like diabetic retinopathy and is expected to enter Phase IIb clinical... Read More
